Biologics are generally effective in treating rheumatoid arthritis, but the specifics vary from person to person.
Currently commonly used biological agents for the treatment of rheumatoid arthritis mainly include tumor necrosis factor α inhibitors (adalimumab, etanercept, etc.), antagonists of interleukin-6 receptor (tolizumab), antagonists of interleukin-1 receptor (anabolic acid), and so on.
Biological agents can, in a relatively short period of time, relieve the symptoms of swelling, pain and morning stiffness of rheumatoid arthritis, and the inflammatory indexes such as blood sedimentation and C-reactive protein will be reduced; long-term use of the drug has a better effect on the bone protection of rheumatoid arthritis patients.
Adverse effects of biological agents are generally mild, mainly localized rash at the injection site, there are some long-term use of patients, may cause easy infection, especially tuberculosis infection, may also lead to an increase in the prevalence of lymphatic system tumors.
It is recommended that patients with rheumatoid arthritis go to the rheumatology and immunology department of a regular hospital, evaluate their condition under the guidance of a doctor and standardize the diagnosis and treatment according to the situation, and undergo regular review.